Practice Guideline Briefs
Am Fam Physician. 2005 Mar 1;71(5):1019-1020.
Treatment of Migraine Headache in Children and Adolescents
The American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society have released a report on treatment of migraine headache in children and adolescents. “Practice Parameter: Pharmacological Treatment of Migraine Headache in Children and Adolescents” appears in the December 2004 issue of Neurology and is available online athttp://www.neurology.org/content/63/12.toc. The guideline has been endorsed by the American Academy of Pediatrics and the American Headache Society.
Migraine headaches are common in children and occur with increasing frequency through adolescence. An estimated 8 to 23 percent of children aged 11 to 15 years experience migraine headaches. The evaluation of a child with recurrent headaches begins with a thorough medical and family history followed by a complete physical examination with measurement of vital signs, particularly blood pressure, and complete neurologic examination including examination of the optic fundi.
Diagnosis of primary headache disorders in children rests principally on clinical criteria as set forth by the International Headache Society (IHS). In 2004, the IHS published a modified International Classification of Headache Disorders (ICHD) for primary and secondary headache disorders (see accompanying box).
2004 International Headache Society Classification of Headache Disorders: Criteria for Pediatric Migraine Without Aura
Five or more attacks fulfilling features B through D
Headache attack lasting 1 to 72 hours
Headache has at least two of the following four features:
Either bilateral or unilateral (frontal/temporal) location
Moderate to severe intensity
Aggravated by routine physical exercise
At least 1 of the following accompanies headache:
Nausea and/or vomiting
Photophobia and phonophobia (may be inferred from their behavior)
Ibuprofen is effective and acetaminophen is probably effective for treating migraine headaches in children and adolescents. Among adolescents, sumatriptan nasal spray is a safe and effective method for migraine treatment. However, none of the oral triptans (rizatriptan, zolmitriptan) were found to be effective in treating migraine in children and adolescents.
According to the guideline, there is insufficient evidence to make recommendations concerning use of preventive agents such as cyproheptadine, amitriptyline, divalproex sodium, topiramate, or levetiracetam. The guideline panel found conflicting outcomes regarding the use of propranalol or trazodone for prevention of migraine, and made no recommendations for its use.
Availability of 24-Hour Clinician Information Line and Addition of Topics
The Clinician Information Line of the Centers for Disease Control and Prevention (CDC) has added three conditions—mass trauma, bovine spongiform encephalopathy (BSE)/variant Creutzfeldt-Jakob disease (vCJD), and viral hemorrhagic fevers—to its expanding list of disease topics.
The information line now covers 16 topics: smallpox, influenza/avian influenza, ricin, severe acute respiratory syndrome, radiation, West Nile virus, chlorine, anthrax, botulism, plague, nerve agents, tularemia, viral hemorrhagic fevers, hurricane recovery, mass trauma, and BSE/vCJD.
Clinicians with questions relating to any of these topics can call the hotline toll-free at 877–554–4625. The hotline is available 24 hours a day, seven days a week, and is staffed by registered nurses with access to the latest CDC guidelines and information. In addition, the nurses can connect callers to their local and state public health departments. Additional information is available online athttp://www.bt.cdc.gov/coca.
Copyright © 2005 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions